6mg retatrutide With retatrutide approaching ~30% weight
Description
Bischoff, Lausanne (Mdecine interne gnrale)
Conflicts of interest Andreas Andersen declares no conflicts of interest
Unadjusted analysis found relatively higher (4 and 5.4% additional) weight loss, HbA1c (0.4% additional) reduction, and fewer gastrointestinal side effects with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg [25]
This addition makes Victoza the only GLP-1 RA product approved for a cardiovascular indication
The good news is that you can meet your nutrient needs through whole foods, even while on a GLP-1 medication
1, there is a complex relationship between the gut and the brain
